Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > End is Nearing Fast
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(625)
•••
Comment by KayakerBCon May 19, 2022 3:14pm
165 Views
Post# 34696211

RE:RE:RE:RE:RE:End is Nearing Fast

RE:RE:RE:RE:RE:End is Nearing FastTalk is cheap! Just like the stock price!  lol

We were talking about the interesting info from Zacks and Dr DR at the end of last year.  Something that might happen (probably) months from now.  And you expect to see it in the stock price now?  LoL.

As far as timelines seems to me you were doing your darness to discourage everyone  with your predictions of like 5 years from now!

Nope, didn't happen.  Nothing 5 years out, or 4, or 3.  Just a 2024 guesstimate for a sustained price above a buck.  That was last August.  Hopefully that's changed because of the Zacks & Dr DR comments and what might happen.

Me discouraging everyone with a prediction?  That's a laugh.  Hypocrisy as usual.  I only have to go back 12 days to find this from you.  

"Please please put me on ignore and don't take me off ignore until we are at $2!
Of course you know that $2 will never come so I'm on ignore forever!"

For some unknown reason I took half a dozen folks off ignore yesterday.  That sure didn't last long.  

(my bolding)
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities